TW202214608A - 稠合噠嗪類衍生物、其製備方法及其在醫藥上的應用 - Google Patents
稠合噠嗪類衍生物、其製備方法及其在醫藥上的應用 Download PDFInfo
- Publication number
- TW202214608A TW202214608A TW110126621A TW110126621A TW202214608A TW 202214608 A TW202214608 A TW 202214608A TW 110126621 A TW110126621 A TW 110126621A TW 110126621 A TW110126621 A TW 110126621A TW 202214608 A TW202214608 A TW 202214608A
- Authority
- TW
- Taiwan
- Prior art keywords
- alkyl
- cancer
- cycloalkyl
- haloalkyl
- heterocyclyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010701561.X | 2020-07-20 | ||
CN202010701561 | 2020-07-20 | ||
CN202011495424.1 | 2020-12-17 | ||
CN202011495424 | 2020-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW202214608A true TW202214608A (zh) | 2022-04-16 |
Family
ID=79728964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW110126621A TW202214608A (zh) | 2020-07-20 | 2021-07-20 | 稠合噠嗪類衍生物、其製備方法及其在醫藥上的應用 |
Country Status (2)
Country | Link |
---|---|
TW (1) | TW202214608A (fr) |
WO (1) | WO2022017339A1 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019217307A1 (fr) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Inhibiteurs de kras g12c |
EP3908283A4 (fr) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | Inhibiteurs de kras g12c |
JP2022546043A (ja) | 2019-08-29 | 2022-11-02 | ミラティ セラピューティクス, インコーポレイテッド | Kras g12d阻害剤 |
MX2022003537A (es) | 2019-09-24 | 2022-07-11 | Mirati Therapeutics Inc | Terapias de combinacion. |
MX2022007515A (es) | 2019-12-20 | 2022-09-19 | Mirati Therapeutics Inc | Inhibidores de sos1. |
EP4319757A1 (fr) | 2021-04-09 | 2024-02-14 | Boehringer Ingelheim International GmbH | Thérapie anticancéreuse |
WO2023280317A1 (fr) * | 2021-07-09 | 2023-01-12 | 南京明德新药研发有限公司 | Composé benzylamino tricyclique et son utilisation |
CN117677398A (zh) | 2021-07-27 | 2024-03-08 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
WO2023135260A1 (fr) | 2022-01-14 | 2023-07-20 | Jazz Pharmaceuticals Ireland Limited | Nouveaux phtalazines à substitution amine et dérivés utilisés comme inhibiteurs de sos1 |
GB202203976D0 (en) * | 2022-03-22 | 2022-05-04 | Jazz Pharmaceuticals Ireland Ltd | Tricyclic phthalazines and derivatives as sos1 inhibitors |
CN114621186A (zh) * | 2022-05-12 | 2022-06-14 | 上海维申医药有限公司 | 作为ras信号通路调控剂的杂环化合物 |
WO2024022507A1 (fr) * | 2022-07-29 | 2024-02-01 | 江苏恒瑞医药股份有限公司 | Composition pharmaceutique comprenant un inhibiteur de kras g12d |
WO2024074827A1 (fr) | 2022-10-05 | 2024-04-11 | Sevenless Therapeutics Limited | Nouveaux traitements de la douleur |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7759337B2 (en) * | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
HUE056777T2 (hu) * | 2016-12-22 | 2022-03-28 | Amgen Inc | Benzizotiazol-, izotiazolo[3,4-b]piridin-, kinazolin-, ftálazin-, pirido[2,3-d]piridazin- és pirido[2,3-d]pirimidin-származékok mint KRAS G12C inhibitorok tüdõ-, hasnyálmirigy- vagy vastagbélrák kezelésére |
EP3558979B1 (fr) * | 2016-12-22 | 2021-02-17 | Boehringer Ingelheim International GmbH | Nouvelles quinazolines substituées benzylamino et dérivés en tant qu'inhibiteurs de sos1 |
MX2022007515A (es) * | 2019-12-20 | 2022-09-19 | Mirati Therapeutics Inc | Inhibidores de sos1. |
-
2021
- 2021-07-20 WO PCT/CN2021/107220 patent/WO2022017339A1/fr active Application Filing
- 2021-07-20 TW TW110126621A patent/TW202214608A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2022017339A1 (fr) | 2022-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW202214608A (zh) | 稠合噠嗪類衍生物、其製備方法及其在醫藥上的應用 | |
WO2020073949A1 (fr) | Régulateur de dérivés hétéroaromatiques contenant de l'azote, procédé de préparation associé et utilisation correspondante | |
CN107108611B (zh) | 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途 | |
WO2021197464A1 (fr) | Dérivés d'imidazole condensés, procédé de préparation correspondant et utilisation médicale associée | |
CN113801114B (zh) | 稠合二环杂芳基类衍生物、其制备方法及其在医药上的应用 | |
TW202115042A (zh) | 芳基磷氧化物類衍生物抑制劑、其製備方法和應用 | |
TW202144338A (zh) | 嘧啶并二環類衍生物、其製備方法及其在醫藥上的應用 | |
TW202214639A (zh) | 吡啶酮并嘧啶類衍生物、其製備方法及其在醫藥上的應用 | |
TW201518278A (zh) | 吡啶酮類衍生物、其製備方法及其在醫藥上的應用 | |
WO2021249475A1 (fr) | Dérivé de quinazoline condensé, son procédé de préparation et son application en médecine | |
TWI826819B (zh) | 一種作為btk抑制劑的化合物及其製備方法與用途 | |
WO2022247816A1 (fr) | Composé hétérocyclique contenant de l'azote, son procédé de préparation et son application dans des médicaments | |
WO2021197452A1 (fr) | Forme cristalline d'un alcali libre de dérivés aromatiques contenant de l'azote | |
TW202128690A (zh) | 吡唑并雜芳基類衍生物、其製備方法及其在醫藥上的應用 | |
TW202328100A (zh) | 含氮雜環類衍生物抑制劑、其製備方法和應用 | |
TW202144353A (zh) | 氮呯類稠環化合物及其醫藥用途 | |
TW202140495A (zh) | 三環四氫異喹啉類衍生物、其製備方法及其在醫藥上的應用 | |
CN115594695A (zh) | 大环类化合物、其制备方法及其在医药上的应用 | |
TW202106693A (zh) | 吲哚類大環衍生物、其製備方法及其在醫藥上的應用 | |
WO2022100738A1 (fr) | Forme cristalline d'une base libre d'inhibiteur contenant un dérivé à noyau bicyclique, procédé de préparation et utilisation de la forme cristalline | |
TW202321241A (zh) | 嘧啶或吡啶衍生物及其製備方法和在藥學上的應用 | |
TW202214642A (zh) | 咪唑并嘧啶類衍生物、其製備方法及其在醫藥上的應用 | |
CN113912608B (zh) | 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用 | |
WO2022161447A1 (fr) | Composé dicarboxamide, son procédé de préparation et son utilisation pharmaceutique | |
WO2024022286A1 (fr) | Inhibiteur d'egfr macrocyclique, son procédé de préparation et son utilisation pharmaceutique |